SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; … Read more
SymBio Pharmaceuticals Limited (SYMQY) - Net Assets
Latest net assets as of December 2025: $1.27 Billion USD
Based on the latest financial reports, SymBio Pharmaceuticals Limited (SYMQY) has net assets worth $1.27 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.87 Billion) and total liabilities ($2.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.27 Billion |
| % of Total Assets | 32.89% |
| Annual Growth Rate | -0.15% |
| 5-Year Change | -81.13% |
| 10-Year Change | -76.79% |
| Growth Volatility | 61.43 |
SymBio Pharmaceuticals Limited - Net Assets Trend (2008–2025)
This chart illustrates how SymBio Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SymBio Pharmaceuticals Limited (2008–2025)
The table below shows the annual net assets of SymBio Pharmaceuticals Limited from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.27 Billion | -69.68% |
| 2024-12-31 | $4.20 Billion | -41.78% |
| 2023-12-31 | $7.21 Billion | -15.24% |
| 2022-12-31 | $8.51 Billion | +26.10% |
| 2021-12-31 | $6.75 Billion | +44.84% |
| 2020-12-31 | $4.66 Billion | +5.85% |
| 2019-12-31 | $4.40 Billion | -10.23% |
| 2018-12-31 | $4.90 Billion | +51.32% |
| 2017-12-31 | $3.24 Billion | -40.94% |
| 2016-12-31 | $5.48 Billion | +23.76% |
| 2015-12-31 | $4.43 Billion | -36.36% |
| 2014-12-31 | $6.96 Billion | -6.32% |
| 2013-12-31 | $7.43 Billion | +51.70% |
| 2012-12-31 | $4.90 Billion | -25.82% |
| 2011-12-31 | $6.61 Billion | +61.78% |
| 2010-12-31 | $4.08 Billion | +0.72% |
| 2009-12-31 | $4.05 Billion | +210.25% |
| 2008-12-31 | $1.31 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SymBio Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3503915382800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $19.26 Billion | 1512.86% |
| Other Comprehensive Income | $361.04 Million | 28.36% |
| Other Components | $19.14 Billion | 1503.81% |
| Total Equity | $1.27 Billion | 100.00% |
SymBio Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of SymBio Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Installux
PA:ALLUX
|
$27.21 Million |
|
352090
KQ:352090
|
$27.22 Million |
|
M2i Global Inc.
OTCQB:MTWO
|
$27.22 Million |
|
SCHMID Group N.V. Warrants
NASDAQ:SHMDW
|
$27.23 Million |
|
Santacruz Silver Mining Ltd.
OTCQB:SCZMF
|
$27.20 Million |
|
TIER 1 TECHNOLOGY EO-01
F:V78
|
$27.20 Million |
|
Asian Insulators PCL
BK:AI
|
$27.20 Million |
|
Calgro M3 Holdings Limited
PINK:CLMHF
|
$27.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SymBio Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,197,559,000 to 1,272,908,250, a change of -2,924,650,750 (-69.7%).
- Net loss of 5,007,740,554 reduced equity.
- Share repurchases of 51,375 reduced equity.
- Other comprehensive income increased equity by 361,040,208.
- Other factors increased equity by 1,722,100,971.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.01 Billion | -393.41% |
| Share Repurchases | $51.38K | -0.0% |
| Other Comprehensive Income | $361.04 Million | +28.36% |
| Other Changes | $1.72 Billion | +135.29% |
| Total Change | $- | -69.68% |
Book Value vs Market Value Analysis
This analysis compares SymBio Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $907.90 | $1.25 | x |
| 2009-12-31 | $2420.91 | $1.25 | x |
| 2010-12-31 | $150872.56 | $1.25 | x |
| 2011-12-31 | $1802.86 | $1.25 | x |
| 2012-12-31 | $1024.52 | $1.25 | x |
| 2013-12-31 | $1283.33 | $1.25 | x |
| 2014-12-31 | $905.04 | $1.25 | x |
| 2015-12-31 | $547.29 | $1.25 | x |
| 2016-12-31 | $557.83 | $1.25 | x |
| 2017-12-31 | $259.89 | $1.25 | x |
| 2018-12-31 | $294.80 | $1.25 | x |
| 2019-12-31 | $190.06 | $1.25 | x |
| 2020-12-31 | $141.34 | $1.25 | x |
| 2021-12-31 | $173.68 | $1.25 | x |
| 2022-12-31 | $214.77 | $1.25 | x |
| 2023-12-31 | $180.69 | $1.25 | x |
| 2024-12-31 | $92.04 | $1.25 | x |
| 2025-12-31 | $25.35 | $1.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SymBio Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -393.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -365.25%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 3.04x
- Recent ROE (-393.41%) is below the historical average (-58.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 1.61% | 1.29% | 1.09x | 1.15x | $-109.67 Million |
| 2009 | -5.37% | -18.29% | 0.28x | 1.05x | $-623.25 Million |
| 2010 | -15.73% | -44.30% | 0.34x | 1.04x | $-1.05 Billion |
| 2011 | -31.86% | -111.79% | 0.26x | 1.10x | $-2.77 Billion |
| 2012 | -35.37% | -88.65% | 0.36x | 1.12x | $-2.22 Billion |
| 2013 | -21.60% | -104.78% | 0.20x | 1.03x | $-2.35 Billion |
| 2014 | -16.02% | -57.08% | 0.26x | 1.07x | $-1.81 Billion |
| 2015 | -59.39% | -136.15% | 0.39x | 1.12x | $-3.08 Billion |
| 2016 | -42.17% | -97.68% | 0.34x | 1.25x | $-2.86 Billion |
| 2017 | -122.80% | -115.49% | 0.81x | 1.31x | $-4.30 Billion |
| 2018 | -56.15% | -71.76% | 0.61x | 1.27x | $-3.24 Billion |
| 2019 | -99.46% | -154.22% | 0.54x | 1.20x | $-4.82 Billion |
| 2020 | -87.82% | -136.93% | 0.48x | 1.35x | $-4.56 Billion |
| 2021 | 30.13% | 24.63% | 0.98x | 1.25x | $1.36 Billion |
| 2022 | 13.86% | 11.78% | 0.96x | 1.23x | $328.63 Million |
| 2023 | -27.22% | -35.11% | 0.68x | 1.13x | $-2.68 Billion |
| 2024 | -91.33% | -156.28% | 0.49x | 1.18x | $-4.25 Billion |
| 2025 | -393.41% | -365.25% | 0.35x | 3.04x | $-5.14 Billion |
Industry Comparison
This section compares SymBio Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SymBio Pharmaceuticals Limited (SYMQY) | $1.27 Billion | 1.61% | 2.04x | $27.21 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |